TRAF6 and chronic obstructive pulmonary disease: In one study, miR-146a incorporated with NCMPs (nanocomposite microparticles) was successfully delivered to reduce IRAK1 (IL-1 receptor-associated kinase) and TRAF6 (TNF receptor-associated factor 6) gene expressions for COPD treatment purposes [166].